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ABSTRACT
Objective: The Identification and Referral to Improve
Safety (IRIS) cluster randomised controlled trial tested
the effectiveness of a training and support intervention
to improve the response of primary care to women
experiencing domestic violence (DV). The aim of this
study is to estimate the cost-effectiveness of this
intervention.
Design: Markov model-based cost-effectiveness
analysis.
Setting: General practices in two urban areas in the
UK.
Participants: Simulated female individuals from the
general UK population who were registered at general
practices, aged 16 years and older.
Intervention: General practices received staff training,
prompts to ask women about DV embedded in the
electronic medical record, a care pathway including
referral to a specialist DV agency and continuing
contact from that agency. The trial compared the rate
of referrals of women with specialist DV agencies from
24 general practices that received the IRIS programme
with 24 general practices not receiving the
programme. The trial did not measure outcomes for
women beyond the intermediate outcome of referral to
specialist agencies. The Markov model extrapolated
the trial results to estimate the long-term healthcare
and societal costs and benefits using data from other
trials and epidemiological studies.
Results: The intervention would produce societal cost
savings per woman registered in the general practice
of UK£37 (95% CI £178 saved to a cost of £136) over
1 year. The incremental quality-adjusted life-year was
estimated to be 0.0010 (95% CI 0.0157 to 0.0101)
per woman. Probabilistic sensitivity analysis found
78% of model replications under a willingness to pay
threshold of £20 000 per quality-adjusted life-year.
Conclusions: The IRIS programme is likely to be cost-
effective and possibly cost saving from a societal
perspective. Better data on the trajectory of abuse and
the effect of advocacy are needed for a more robust
model.
Trial registration: Current Controlled Trials,
ISRCTN74012786.
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ARTICLE SUMMARY
Article focus
- The aim of this study was to assess the cost-
effectiveness of the IRIS training and support
intervention for primary care clinicians from the
UK societal and NHS perspectives.
Key messages
- The intervention is likely to be cost saving from
a societal perspective with a high likelihood of
being under a £20 000 per quality-adjusted life-
year willingness to pay threshold.
Strengths and limitations of this study
- We have minimised bias in estimating the effect
size of the IRIS programme by basing it on
a randomised controlled trial.
- By using epidemiological and cost data external
to the trial, we were able to extrapolate from
directly measured trial outcomes (DV disclosure
and referral rates) to quality of life, health and
economic outcomes.
- The uncertainty of the transition probabilities
based on assumptions was addressed by
probabilistic sensitivity analysis, contributing to
the robustness of the model.
- Important limitations of that data are the paucity
of longitudinal studies measuring the trajectory
of abuse and uncertainty about the effect of DV
advocacy for women not living in a refuge or
shelter.
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INTRODUCTION
Domestic violence (DV) is threatening behaviour,
violence or abuse (psychological, physical, sexual,
financial or emotional) between adults who are in the
same family or who are or have been intimate partners.
The lifetime population prevalence of physical and
sexual violence against women varies internationally
from 15% to 71%.1 This large variation reflects different
measures of abuse, as well as actual differences in
national, regional and local prevalence. Survivors suffer
chronic health problems including gynaecological
problems,2 gastrointestinal disorders,2 neurological
symptoms,2 chronic pain3 and cardiovascular condi-
tions.4 The impact on mental health, including post-
traumatic stress disorder, depression, anxiety and
substance abuse,5 6 can persist long after the violence has
ceased. In 2008, the aggregate UK cost estimate for DV,
including medical and social services, lost economic
output and emotional costs, was £15.7 billion ($29.1
billion).7 While estimates of the cost burden can help
highlight the importance of the issue in policy terms, we
also need to link the size of the economic impact to
estimates of how this can be reduced through interven-
tions in order to make an economic case for investment
in DV programmes. To do this, we need to combine
evidence of the costs experienced by groups with and
without a DV intervention with evidence of the outcomes
experienced by those two groups in an economic eval-
uation.8 Here, we report an economic evaluation of DV
interventions based on a randomised controlled trial,
the least biased method for measuring the effect of an
intervention.9
Healthcare may be a survivor’s first or only point of
contact with professionals, and abused women are more
likely to contact health services than any other agency.10
The magnitude of the health consequences of DV
contrasts starkly with its virtual invisibility within primary
healthcare; in one UK general practice-based question-
naire study, only 15% of women with a history of DV had
any reference to violence in their medical record.11 If
women disclose DV to a clinician, whether in a primary
care or specialist setting, there is evidence of an inap-
propriate poor-quality response.12 Doctors and nurses
are largely unaware of appropriate interventions and
have seldom received effective or, in the UK, any
training11; yet abused women identify doctors as the
professionals from whom they would most like to seek
support.12
The Identification and Referral to Improve Safety
(IRIS) trial13 tested the effectiveness of a training and
support intervention for general practice teams,
including training within the practice, a prompt to ask
about DV embedded in the electronic medical record,
a care pathway including referral to a specialist DV
agency and continuing contact from that agency.
Recorded referral in the medical record was 22 times
greater in the intervention practices compared with the
control practices and referral received by DV agencies
was seven times greater. These agencies provided
specialist advocacy to women experiencing DV: access to
refuges/shelters, emergency housing, psychological
services and ongoing support, as well as provision of
information on legal, housing and financial options. In
this paper, we present an economic evaluation of the
IRIS programme (box 1), refining a previous model
based on a pilot study of the intervention.14
METHODS
We conducted a cost-effectiveness analysis based on
a comparison of the 24 intervention with 24 control
practices in the IRIS trial (143 868 eligible women
patients). We constructed a Markov model to estimate
lifetime quality-adjusted life-years (QALYs) and costs
Box 1 Description of the Identification and Referral to
Improve Safety (IRIS) programme
The primary intervention consisted of two 2 h multidisci-
plinary training sessions, targeted at the clinical team. The
training sessions were designed to address the expressed
and tacit barriers to improving the response of clinicians to
women experiencing abuse through improved identification,
support and referral to specialist agencies. These sessions
incorporated case studies and practice in asking about
violence and responding appropriately. They were delivered
by an advocate educator based in one of the two collabo-
rating specialist agencies, and either a clinical psychologist
specialising in domestic violence or an academic general
practitioner. The advocate educator was central to the
intervention, combining a training and support role to the
practices with provision of advocacy to women referred
from the practices. The training sessions were followed by
periodic contact with the practice in clinical meetings,
feeding back anonymised practice data on disclosure and
referral to the advocacy service, and reinforcing guidance
on good practice with regard to domestic violence, as well
as ad hoc telephone conversations and email exchanges
with clinicians about referrals or advice. One-hour training
sessions with administrative staff focused on issues of
confidentiality and safety for patients experiencing abuse
and introduced the IRIS information materials signposting
domestic violence agencies. Ongoing support to clinicians
and reception staff in the practices was provided by the
named domestic violence advocate educator, with the aim
of consolidating the initial training. Intervention practices
also were asked to identify a ‘champion’ for the project; with
the agreement of the practice, a member of staff from any of
the clinical disciplines was invited to attend an additional
2.5 days of training about domestic violence and to inte-
grate this into the work of the practice. Other components of
the intervention included a template in the electronic
medical record linked to diagnoses (such as depression,
anxiety, irritable bowel syndrome, pelvic pain and assault),
an explicit referral pathway to a named domestic violence
advocate and publicity materials about domestic violence
visible in the practices. Clinicians were trained to have a low
threshold for asking about domestic violence as a ‘clinical
enquiry’, not screening.
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from a UK national health service and a societal
perspective. Markov modelling is a technique for esti-
mating the costs and outcomes in a hypothetical cohort
of women over time. We simulated a cohort of 10 000 UK
representative women with and without the IRIS
programme and used the differences between the two
simulations to calculate the incremental costs and
outcomes associated with IRIS. We report our findings in
terms of costs, QALYs and incremental costs per QALY
gained. In the UK, an incremental cost-effectiveness
ratio, which is the ratio of differences between the costs
of two alternatives and the difference between their
effectiveness, of less than UK£20 000e30 000 (US
$37 122eUS$55 683) is generally thought to be cost-
effective by policy makers.15 To construct the Markov
model, we defined a set of mutually exclusive and
exhaustive states experienced by women in relation to
DV. The model then simulated the hypothetical cohort
of women moving between the states, using a matrix of
transition probabilities reflecting the likelihood of
moving from each state to every other state within each
discrete time period (in this case, 6 months, as this is the
average amount of time a woman stays in contact with
advocacy services).16 In order to aid comparison with the
model for the pilot intervention,14 a 10-year time
horizon was used, and future costs and outcomes were
discounted at 3.5%.17
Model structure
We drew upon the model that was developed to estimate
the long-term cost-effectiveness of the pilot intervention,
Prevention of Domestic Violence (PreDoVe).14 The IRIS
model was based on fewer assumptions about women’s
trajectories into and out of abuse and we used trial data
instead of pilot data. In the IRIS Markov model (figure 1),
the possible states of individual women were as follows:
< No abuse: women not experiencing DV
< Abuse unidentified: women who are experiencing abuse
but have not been identified by a healthcare
professional
< Advocacy: women who are experiencing abuse and
have seen or are seeing a DV advocate
< Identified existing victim: women who are experiencing
abuse and have been recognised as such by a health-
care professional but are not seeing an advocate
< Death: women who have died from DV or other causes
We excluded states that could not be informed by
contemporary reliable data. For example, PreDoVe
included a state to represent the medium-term
improvement of women whose condition had improved
but had not yet reached the point where they were
completely free of abuse.14 This state was intended to
reflect a stage on the trajectory to living without abuse,
and we hoped that in the IRIS model the costs and
quality of life (QoL) associated with this state would
be informed by new studies. No relevant epidemiological
studies have been reported, so we omitted this inter-
mediate state and incorporated the effects of the inter-
vention in the remaining states in order to reduce
the number of transition probabilities based on
assumptions.
The states are simplified in relation to available data.
For example, the advocacy state includes identification
and referral of women to an advocate. There are some
transitions between states that we know might exist in
the long term, such as between identified existing victim
and advocacy (denoting self-referral of women to advo-
cacy after they have disclosed to a healthcare profes-
sional), but for which we have no data. We envisage that
this transition rate would be very small and so we do not
expect any material changes in the model results if this
transition was included. In other key areas, however, the
IRIS model was able to distinguish more clearly the
movement of women over time, as a result of improved
data collection within the trial. For example, IRIS data
distinguished between a referral recorded in the clinical
record, a referral received by the agency and actual
attendance by the patient, whereas the PreDoVe model
was not able to distinguish between these outcomes.
This model structure is informed by the epidemiology
of DV, including a cross-sectional study11 of prevalence
in general practice populations similar to the IRIS
sample, the trajectory of abuse18 and estimates of the
effect of DV advocacy on cessation of abuse and
improvements in QoL and psychological outcomes.19
Research by Bybee and Sullivan has contributed both to
the small group of longitudinal studies of women expe-
riencing DV20 and provided the most robust estimates of
the effects of advocacy.21
Transition probabilities
In the IRIS model, the advocacy state only included
those women who had contact with the advocate,
a more accurate estimate of exposure to advocacy than
the primary outcome of the trial, which was referral toFigure 1 Markov model diagram.
Devine A, Spencer A, Eldridge S, et al. BMJ Open 2012;2:e001008. doi:10.1136/bmjopen-2012-001008 3
Domestic violence cost-effectiveness
 group.bmj.com on February 25, 2014 - Published by bmjopen.bmj.comDownloaded from 
advocacy noted in practice records but did not neces-
sarily indicate that the woman saw an advocate.
The advocacy state also included women who self-
referred to advocacy as a result of a poster or card in
the practice drawing attention to the service. The
identified existing victim state consisted of women iden-
tified as experiencing abuse but not having contact
with the advocate.
The number of women being identified (ie, the tran-
sition probability from abuse unidentified to identified
existing victim) and seen by an advocate (abuse unidentified
to advocacy) was significantly different for women in the
intervention and control practices (table 1). The transi-
tion probabilities for recovery from abuse were drawn
from a systematic review19 of the rate of recovery from
physical abuse for women in intensive advocacy, which
was largely based on a trial by Sullivan and colleagues
recruiting IPV survivors in shelters (refuges) and
following them up in the community for 3 years.24 In our
model, we reduced the probability of transition to the
non-abused state by 75% to account for the lower
intensity of the IRIS intervention compared with those
in the advocacy trials.
All-cause mortality for women in the UK aged 16 years
and older in 2008 was 0.011646 (264 031/22 671 300).22
For women experiencing DV, mortality resulting from
DV (MDV) was 0.00019 (102/529 000).
23 The mortality
rate from DV for all women was calculated (102/
22 671 300) and subtracted from the death rate for all
women to get 0.011642, the annual mortality rate for
women not experiencing DV (MNA). The annual
mortality rate for women experiencing abuse (MA) was
estimated to be 0.011834 (MNA + MDV). The six-monthly
probabilities used in our model are shown in table 1.
The IRIS model captured the movements of all women
registered at the practice aged 16 years and older, with
a death rate to match this age bracket, more accurately
reflecting the exposure of older and younger women to
the intervention than the PreDoVe model that only used
a death rate for women aged 16e45 years, while still
estimating the total population costs and benefits of the
intervention. The transitions are provided in table 1.
Intervention costs
Intervention costs were directly measured in the trial
(table 2). The total six-monthly intervention costs were
divided by the number of registered women in the
intervention practices.
Advocate educator
The advocate educator was central to the IRIS inter-
vention, combining a role in training and support to the
practices with provision of advocacy to women referred
from the practices.13 27 The advocate educator
Table 1 Model assumptions and sources for the six-monthly transition probabilities
Assumption Mean value
Distribution for
sensitivity analysis* Notes
No abuse to abuse unidentified (A) 0.0075 Lognormal (0.75) Assumption
Abuse unidentified to no abuse (B) 0.025 Lognormal (0.75) Assumption
No abuse to no abuse (C) 0.9867 Complementary to A + K
Control: abuse unidentified to
identified existing victim (D)
0.0094 Lognormal (0.1) From IRIS
Intervention: abuse unidentified to
identified existing victim (D)
0.0207 Lognormal (0.1) From IRIS
Control: abuse unidentified to
advocacy (E)
0.0016 Lognormal (0.1) From IRIS
Intervention: abuse unidentified to
advocacy (E)
0.0101 Lognormal (0.1) From IRIS
Control: abuse unidentified to abuse
unidentified (F)
0.9581 Complementary to D + E + L
Intervention: abuse unidentified to
abuse unidentified (F)
0.9383 Complementary to D + E + L
Advocacy to no abuse (G) 0.0888 Lognormal (0.75) Ramsay et al19 intervention arm
reduced by 75% to reflect lower
ntervention intensity in IRIS
Advocacy to advocacy (H) 0.9053 Lognormal (0.75) Complementary to G + L
identified existing victim to no abuse (I) 0.0717 Lognormal (0.75) Ramsay et al19 control arm reduced
by 75% to reflect lower intervention
intensity in IRIS
identified existing victim to
identified existing victim (J)
0.9223 Complementary to I + L
Death rate if not being abused (K) 0.0058 Lognormal (0.75) All-cause mortality22
Death rate if being abused (L) 0.0059 Lognormal (0.75) All-cause mortality22 + Walby23
*SDs are listed for the lognormal distributions and standard variances for the b distributions. The SDs used in the model were found by
multiplying these numbers by the listed values (eg, the SD for transition rate A ¼ 0.007530.75¼0.0056).
IRIS, Identification and Referral to Improve Safety.
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conducted training sessions, gave ongoing support to
the practice and initial management of women referred
by the practices. The advocate educator costs included
salary, on costs and management costs, and the inclusive
hourly cost was estimated to be £34. We deducted the
cost of time allocated to research support. We did not
adjust costs by practice size or by volume of referral
because (1) the advocate educator salary costs were fixed
at the start and (2) the practices that referred dispro-
portionately fewer women, with a smaller impact on
advocate caseload required greater training and support
input to encourage increased engagement with the
programme, increasing the workload of the advocate.
Other training time and costs
A clinical psychologist attended one of the two training
sessions per practice and an academic general practi-
tioner (GP) attended the other. We costed the allocated
time rather than the actual training time, as the latter
varied, but the prospective time commitment was fixed.
We made the conservative assumption that training
would need to be repeated annually with the same (and
new) staff in attendance. We used the cost of practice
reimbursement for trial participation to offset the costs
of staff time spent in the training sessions.
Costs of onward referral from advocates
Within the IRIS trial, 57% of women in contact with an
advocate were given an onward referral within the
agency or to an external agency. Of those given an
onward referral, 63% accepted it. The amount of time
per onward referral varies greatly. We assumed an
average of 57 h per onward referral to other advocacy
services based on the main Sullivan trial that informed
our estimate of the effect of advocacy24 28 less the time
spent by advocate educators within the IRIS interven-
tion. In this way, we were able to link the costs associated
with advocacy with the transition rates out of the identi-
fied existing victim and advocacy states.19 28 The cost per
hour of an onward referral was drawn from the advocate
educator unit costs.
Costs and outcomes of abuse
For costs associated with events beyond the measured
trial outcomes (identification and referral to DV advo-
cacy), estimations were drawn from Walby’s analysis of
the societal and personal costs incurred by women
experiencing abuse (table 3).23 While these figures were
updated in 2009, the report noted that DV has decreased
while services for victims have increased, resulting in
similar overall cost figures to those in the original
report.7 Healthcare costs for major medical events and
additional primary care visits related to abuse were
included. We assumed that the cost of abuse would be
the same, regardless of whether women had been iden-
tified or referred to an advocate.
QoL for the states involving abuse (abuse unidentified,
identified existing violence and advocacy) was taken from
survey data by Wittenberg and colleagues and can be
found in table 226 29; QoL for women in no abuse was
taken from the female subset of a UK general population
survey.25
Table 2 Model assumptions and sources for the costs and utilities
Category Assumption Mean value
Sensitivity analysis
distribution Notes
Intervention
costs*
Advocate salaries and
travel costs
£24518 0.9 fte including employer National
Insurance contribution and
management costs from IRIS.
Clinical staff time and travel
to lead training sessions
£3766 From IRIS
Administration costs £1401 From IRIS
Practice reimbursement £9413 From IRIS
Total cost for the intervention £39097 Lognormal (0.1) From IRIS
Number of women intervention
costs divided by
70 521 Lognormal (0.1) From IRIS
Cost per woman registered £0.55 From IRIS
Onward referral £823 Lognormal (0.75) A one-time cost for women entering
the advocacy state from abuse
unidentified from IRIS + Sullivan et al24
State costs No abuse £102 Lognormal (0.25) Walby23 Distribution is an assumption.
Abuse unidentified £4721 Lognormal (0.25) Walby23 Distribution is an assumption.
Identified existing victim £4721 Lognormal (0.50) Walby23 Distribution is an assumption.
Advocacy £4721 Lognormal (0.75) Walby23 Distribution is an assumption.
Utilities No abuse 0.85 b (0.00181) Kind et al25
Abuse unidentified 0.63 b (0.01588) Wittenberg et al26
Identified existing victim 0.63 b (0.01588) Wittenberg et al26
Advocate 0.65 b (0.01525) Wittenberg et al26
*Costs are in 2008 UK pounds.
IRIS, Identification and Referral to Improve Safety.
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Model calibration
As there was considerable uncertainty surrounding
a number of the transition probabilities, we used known
prevalence figures11 to calibrate the model. The model
was run until steady states for the population in each
group were achieved, allowing comparison with these
known prevalence figures. If these figures were very
dissimilar, the transition rates that had the most uncer-
tainty around them were adjusted accordingly. The rates
with the most uncertainty were the rate from no abuse to
abuse unidentified and the rate from abuse unidentified to
no abuse as there are no empirical studies to inform the
assumptions. Steady states determined the initial distri-
bution of women in the model.
The model calibration demonstrated that the rates
from no abuse to abuse unidentified and the rate from abuse
unidentified to no abuse needed to be adjusted. The rate of
spontaneous recovery from abuse (abuse unidentified to no
abuse) was increased from 0.005 (PreDoVe assumption)
to 0.025. To compensate for this increase, the rate from
no abuse to abuse unidentified was raised from 0.0027 to
0.005. With these adjustments, the model better
reflected the population prevalence of abuse at 19.3%.11
Starting populations for each state were 80.7% in no
abuse, 16.8% in abuse unidentified, 0.3% in advocacy and
2.2% in identified existing victim.
Cost-effectiveness analysis
The costs and outcomes along with the intervention
costs described above were applied to the model states as
appropriate. All costs and benefits were reported in 2008
British pounds to reflect the trial setting; costs taken
from other years were adjusted as appropriate.30
We determined the mean incremental costs and
incremental QALYs of implementing the IRIS approach
relative to usual care delivered in the control practices
and reported incremental cost-effectiveness ratios. Non-
parametric bootstrapping with 1000 iterations was used
to calculate 95% CIs for the incremental costs and
incremental QALYs. As this is a public health interven-
tion, the initial analysis was from a societal perspective
with a secondary analysis focusing on costs and cost-
effectiveness from a healthcare provider perspective.
The secondary analysis only included costs of medical
service and mental health consequences for women.
Sensitivity analysis
To assess the robustness of our result, we performed
a probabilistic sensitivity analysis (PSA) on the model
using appropriate distributions for each variable.
Generally, distributions reflected the certainty of the
data source with SDs of 10% of the mean for values from
the trial and 75% for assumptions and values from the
literature (tables 1 and 2). To calculate the parameters
for the b distributions used for the QoL data, we made
an assumption about the linearity of the sample vari-
ances for each state so that the sample variance
decreased as the QoL value increased. To ascribe
potential cost benefits for women who have received
help from an advocate, we made the assumption that the
SD for the advocacy state was 0.75. Given that identifica-
tion alone can confer some benefit, we assumed that the
SD for the identified existing victim state was 0.50.
RESULTS
The intervention arm demonstrated a societal cost
savings per woman registered of UK£37 (US$67) (95%
CI UK£178 saved to a cost of UK£136 (US$330 to US
$253)) per year. The incremental QALY was estimated to
be 0.0010 (95% CI 0.0157 to 0.0101) gained per
woman (table 4). Since the intervention programme
demonstrated lower costs and higher effectiveness, it
dominated current practice. When only NHS costs for
medical attention and mental health were considered,
the result was a cost savings of UK£1.07 (US$1.99) per
woman per year, which is equivalent to UK£3155 (US
$5851) per practice per year.
These projected savings are calculated per woman
registered in a practice and not all women will enter into
an abusive relationship. The small NHS cost savings per
woman per year are substantial when aggregated at
a practice level. Costs decrease because more women
leave the abuse unidentified state with more entering into
the no abuse state. In the broader societal perspective, the
annual projected savings from the IRIS intervention are
striking.
Sensitivity analysis
The PSA also had 78% of model replications under
a willingness to pay threshold of UK£20000 (US$37122)
Table 3 Average six-monthly costs for women from
Walby23 (2008 UK pounds)
No abuse Abuse*
Criminal justice £0 £983
Civil justice £36 £355
Employment loss of output £0 £2439
Medical services £0 £184
Mental health £63 £250
Social services and childcare £0 £487
Temporary housing £3 £23
Total six-monthly costs £102 £4721
*These costs were used for the abuse unidentified, identified
existing violence and advocacy states.
Table 4 Results per registered woman over 1 year
Control Intervention
Mean difference
(95% CI)*
Discounted
societal costs
1610 1574 £37 (£178
to £136)
Discounted
NHS costs
218 217 £1 (£15
to £17)
Discounted
QALYs
0.6544 0.6554 0.0010 (0.0157
to 0.0101)
*Negative costs favour the intervention, while negative quality-
adjusted life-years (QALYs) favour the control.
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per QALY (figure 2). The key drivers of uncertainty were
the transition rate from identified existing victim to no abuse,
the QoL associated with the abuse unidentified state and
employment loss of output costs due to abuse. The ICER
was not sensitive to changing the time horizon to 20 years
as the costs and outcomes associated with the intervention
were almost uniformly distributed over time.
DISCUSSION
This is the first economic evaluation of a DV interven-
tion in the context of a randomised controlled trial. We
found that the IRIS programme is likely to be cost-
effective and possibly cost saving from a societal
perspective and a healthcare perspective in the UK. The
relatively modest costs of the primary care-based inter-
vention and its projected long-term cost benefits means
this is likely to be the case in other developed healthcare
economies.
We have minimised bias in estimating the effect size of
the IRIS programme by basing it on a randomised
controlled trial that evaluated a crucial link between
healthcare and access of women to specialist DV services.
By using epidemiological and cost data external to the
trial, we were able to extrapolate from directly measured
trial outcomes (DV disclosure and referral rates) to QoL,
health and economic outcomes. The uncertainty of the
transition probabilities based on assumptions was
addressed by PSA, contributing to the robustness of the
model. By reporting societal as well as healthcare cost-
effectiveness, our findings can inform societal prioriti-
sation of investment in relation to DV as well as specific
decisions at a healthcare commissioning level.9
This model was an improvement on the previous
version developed in the pilot study, which preceded the
Cochrane review of advocacy trials to inform some of the
key transition rates. This pilot study only involved four
practices and was based on a non-randomised compar-
ison, and the model did not use a PSA to characterise the
uncertainty of the cost-effectiveness estimate.
The DV prevalence of 17% came from women
attending general practice rather than all women
registered at the practice. As not all women see their GP
and as women experiencing abuse are likely to see their
GP more often than the general population, this figure
is potentially higher than it should be for the popula-
tion of women in our model. This may have over-
estimated the cost-effectiveness of the intervention.
Research by Fishman and colleagues31 in the
USA indicates that we may be underestimating the
higher healthcare costs in women in the years following
cessation of abuse, but no research has quantified these
costs in a UK setting. Our model does not include
any benefits of the intervention for children who are
exposed to DV,32 underestimating the potential cost-
effectiveness. The downstream benefit of the interven-
tion on women is crucially dependent on trials
from one centre in the Cochrane systematic review of
the effectiveness of advocacy, which evaluates
women receiving intensive (60 h) DV advocacy in the
context of a refuge (shelter). To guard against
a potential overestimate of benefit in our model, we
used this effect reduced by 75% to extrapolate the
Cochrane review findings to community-dwelling
women referred to less intensive advocacy from primary
care. Our projections of longer term benefit of DV
advocacy were problematic because trials in this field
measure relatively short-term outcomes. Moreover,
there is a dearth of longitudinal studies measuring the
medium- to long-term trajectory of DV events in terms
of continuing or repeated abuse and no prospective
medium- or long-term data on QoL and health status
following abuse.
As Gold and colleagues9 argue in their methodological
paper on evaluating the cost-effectiveness of healthcare
programmes for partner violence, the resources
required to provide effective interventions that reduce
violence and improve outcomes for women could be
used for other healthcare interventions or social
care programmes. Despite the growth in the number
of randomised controlled trials, the analysis of cost-
effectiveness within the field of DV research is still
embryonic. Given the long-term benefits of cessation of
violence and the necessarily limited follow-up in trials, as
well as the particular challenges of following up partici-
pants who have experienced DV,33 models such as the
one we have reported here are essential in evaluating the
cost-effectiveness of DV programmes in healthcare and
other settings. The robustness of these models will be
improved by longitudinal studies characterising the
different trajectories of abuse and their sequelae.
Notwithstanding the need for better longitudinal data to
populate these models, the analysis that we have
reported in this paper is evidence of cost-effectiveness
that can inform the commissioning of the IRIS
programme in the context of primary healthcare
services.
Figure 2 Cost-effectiveness acceptability curve. Probability
that the Identification and Referral to Improve Safety (IRIS)
intervention is cost-effective after 10 years plotted as a function
of societal willingness to pay per quality-adjusted life-year.
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